KMDA
Kamada Ltd
stockNASDAQ
kamada ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. the company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce alpha-1 antitrypsin (aat) in a highly-purified, liquid form, as well as other plasma-derived proteins. aat is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. the company's flagship product is glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived aat product approved by the u.s. food and drug administration. kamada markets glassia in the u.s. through a strategic partnership with baxter international. in addition to glassia, kamada has a product line of nine other pharmaceutical products that are marketed through distributor
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 8.70 | 2026-09-29 | -7.76% | 2.209 |
| 1M | 8.29 | 2026-09-08 | -3.26% | 0.457 |
| 3M | 7.49 | 2026-07-06 | +7.08% | 0.403 |
| 6M | 8.28 | 2026-04-06 | -3.14% | 0.778 |
| 1Y | 6.70 | 2025-10-06 | +19.70% | 1.018 |
| 2Y | 5.24 | 2024-10-07 | +53.05% | — |
| 5Y | 5.25 | 2021-10-06 | +52.76% | 0.680 |
Kamada Ltd (NASDAQ:KMDA) stock price today is $8.02, and today's volume is 137,513. KMDA is down 3.490% today. The 30 day average volume is 141,135. KMDA market cap is $462.84M with 57.71M shares outstanding.